BertrandMAnzIIIMD

Oncology • Chattanooga, TN

Physician

Join to view full profile

Dr. Anz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Anz's full profile

Already have an account?

Office
605 Glenwood Drive
Suite 200
Chattanooga, TN 37404
Phone+1 423-698-1844

Fax+1 423-624-2226
Is this information wrong?

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2004 - 2007
University of South Alabama College of MedicineClass of 2004

Certifications & Licensure

TN State Medical License 2010 - 2026
GA State Medical License 2010 - 2025
AL State Medical License 2020 - 2020
NC State Medical License 2004 - 2010
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012

Clinical Trials

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2

Publications & Presentations

PubMed

59 citations
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumabchlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMI...
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz
Haematologica. 2022-09-01
383 citations
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, ope...
Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz
The Lancet. Oncology. 2019-01-01
8 citations
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-rel...
Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag
Leukemia & Lymphoma. 2022-06-01

Abstracts/Posters

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
Bertrand M. Anz III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Hospital Affiliations

CHI MemorialChattanooga, Tennessee
Parkridge Medical CenterChattanooga, Tennessee